01/11/2015

Ariberto Fassati

What is AIDS?
Acquired ImmunoDeficiency Syndrome
First reported in 1981 in 5 North American gay men
www.cdc.gov/mmwr/PDF/wk/mm5021.pdf

Virus first isolated in France and USA

Barre-Sinoussi F, et al. Science. 1983 220: 868-71

Popovic M, Science. 1984 May 4;224(4648):497-500
CDC's definition of AIDS includes all HIV-infected people who have
fewer than 200 CD4+ T cells per cubic millimeter of blood
http://www.niaid.nih.gov/factsheets/hivinf.htm

And presents with:

Profound immune deficiency, Opportunistic infections and Kaposis Sarcoma
Lymphadenopathy, wasting, fever, pneumonia.
Very low CD4+ T cells, high CD8+ T cells (inverted T4:T8 ratio)

Acute HIV-1 infection presents as:

Asymptomatic or fever, headache, tiredness, generalised swollen glands

01/11/2015

01/11/2015

01/11/2015

HIV/AIDS: how?
Chimpanzee

Gorilla

Sooty mangabey

SIVcpz

SIVgor

SIVsm

HIV-1 M

HIV-1 O

HIV-2

Phylogenetic tree of HIVs and SIVs

Based on sequencing data

01/11/2015

/AIDS

Different dynamics of HIV-1 O and HIV-1 M

Faria et al. Science 2014 346: 56.

01/11/2015

HIV-1 variation and the pandemic

Group N: discovered in 1998 in Cameroon (rare)
Group O: outlier in West-Central Africa
Group M: major worldwide
Clade B and recombinants thereof are
dominant in North and South America,
Western Europe and Australasia
Clades A and C and recombinants are
dominant in China, India, sub-Saharan
Africa and parts of Russia.

Consequences for
1) Vaccine design
2) Diagnosis
3) Pathogenesis

HIV-1 sequence variability

01/11/2015

HIV/AIDS: when?
Date of origin of HIV-1: around 1920
First virus isolate available to date: 1952 from Kinshasa (DR Congo)
First retrospective case of HIV-1 seroconversion (infection): 1959
in Kinshasa.
First 5 cases reported in 1981 in USA
(Gottlieb et al. 1981 N. Engl. J. Med 305: 1425)
Number of deaths directly due to AIDS to 2007: >24 million
Number of people infected with HIV-1 at 2008: ~32 million

HIV/AIDS: where?

01/11/2015

Samples (from 1960) recovered from hospital in Congo showed that the epidemic probably started
around 1908

01/11/2015

Faria et al. Science 2014 346: 56.

II. HIV Life cycle

01/11/2015

HIV-1 genome organization

Approximately 9Kb

10

01/11/2015

Structure of the mature HIVHIV-1 particle

The outer envelope of
HIV consists of a lipid
bilayer with protruding
Env spikes
(heterotrimers of
SU3TM3). Inside the
envelope lie shells of
Gag proteins. In the
immature particle, Gag
itself forms a single
shell.

In the mature particle, MA associates with the membrane, CA forms the

conical capsid, and NC coats the viral RNA genome. The core contains two
genomic RNA strands (plus strand), tRNALys3, and ~50 copies of each viral
enzyme (PR, RT, and IN). Cellular proteins are also incorporated eg
Cyclophilins

Image Reconstruction of HIV-1 Cores

Li, S., C. P. Hill, W. I. Sundquist, and J. T. Finch. 2000.

Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407:409-13.

11

01/11/2015

Robert W. Doms et al. Genes Dev. 2000; 14: 2677-2688

Major co-receptors: chemokine receptor CCR5 and CXCR4. CCR5 is essential for virus
transmission in vivo, present on T-helper lymphocytes, macrophages, microglial cells.
CXCR4 used in the late phase of the infection.

12

01/11/2015

Reverse transcription:

The RNA genome (two +strands of RNA)

is converted into a double stranded DNA
molecule by reverse transcriptase (RT), a
viral enzyme.

Reverse Transcription
5 R U5 PBS
tRNA

PPT

U3 R

AAA 3

DNA synthesis

R U5 PBS

PPT

U3 R

PPT

U3 R AAA

AAA

RNase H
PBS
R U5

First strand transfer

PBS

PPT
DNA synthesis
RNase H

PBS

PPT

PBS

DNA synthesis
RNase H
PPT

U3 R AAA
R U5

U3 R U5
U3 R U5

U3 R U5

U3 R U5
Second strand transfer
DNA synthesis
U3 R U5

U3 R U5

U3 R U5

13

01/11/2015

Visualisation of HIV-1 inside an infected cell. The RTC/PIC travels along microtubules and is
a large structure composed of viral and cellular factors. Reverse transcription takes place within
this structure.

Integration and generation of a provirus

Two bases are removed from the

3 end of both viral DNA strands
by integrase
Cellular DNA is cleaved by
Integrase leaving two 4bp
overhangs

The 3 ends of viral DNA are

Joined to the host DNA a few
bases apart
Gaps and mismatches are
Repaired by cellular enzymes
And a 4 bp duplication is
formed at the end of the provirus

14

01/11/2015

15

01/11/2015

Protease

MLV

Changes in virion
morphology during maturation
MPMV

HTLV

HIV

III. HIV-1 infection

16

01/11/2015

HIV-1 cellular tropism defined by

receptor usage
R5

R5X4

X4

CD4+ T

Dendritic,
Langerhans

Macrophage

Activated/
effector memory

?
Microglia

naive

CD4
CCR5
CXCR4

Astrocyte

1) HIV may be picked up by inter-digitating

DCs and Langerhans cells (DC-SIGN or
direct infection) and shuttled to the draining
lymph nodes
2) HIV may cross the epithelial barrier
via damage to epithelium from trauma or
co-infection with other agents and directly
infect Lamina Propria CD4+ target cells
3) HIV may be able to transcytose across the
epithelial monolayer of the ecto-cervix to
access Lamina Propria
Initial seeding leads to massive
dissemination to all lymphoid tissue within
3 weeks on infection

17

01/11/2015

The natural history of HIV

infection
Average time to AIDS ~10
years post infection

Total CD4 T cells

Acute phase (1-4 weeks),

Antibodies present after 4
weeks (diagnostic).

HIV-specific CD8 T cells

HIV-specific neutralising antibody

Neutralising Abs appear

later in the course of
infection.

Viral load (RNA)

HIV-specific CD4 T cells

0

Primary
Infection
(months)

Asymptomatic (clinical latency)

(years)

10
AIDS

11

Anti-HIV CD8 T-cells

detected ~2 weeks after
infection, contribute to
control viral replication

V. Antiretrovirals

18

01/11/2015

Approved Antiretrovirals
Brand name
Generic name
Nucleoside reverse transcriptase inhibitors (NRTIs)
Retrovir
Zidovudine (AZT
Videx
Didanosine (ddI)
Hivid
Zalcitabine (ddC)
Zerit
Stavudine (d4T)
Epivir
Lamivudine (3TC)
Combivir
Lamivudine+Zidovudine
Ziagen
Abacavir
Trizivir
Abacavir+lamivudine+zidovudine
Videx EC
Didanosine (ddI)
Viread
Tenofovir disoproxil
Emtriva
Emtricitabine (FTC)
Epzicom
Abacavir+Lamivudine
Truvada
Emtricitabine+Tenofovir
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Viramune
Nevirapine
Rescriptor
Delavirdine (DLV)
Sustiva
Efavirenz
Intelence
etravirine
Protese Inhibitors (PIs)
Aptivus
Tipranavir (TPV)
Invirase
Saquinavir
Norvir
Ritonavir
Crixivan
Indinavir (IDV)
Viracept
Nalfinavir
Fortovase
Sequinavir Mesylate
Agenerase
Amprenavir
Kaletra
Lopinavir+Ritonavir
Reyataz
Azatavir
Lexiva
Fosemprenavir
Fusion Inhibitors
Fuzeon
Enfuvirtide (T20)
Entry inhibitors
Selzentry
Maraviroc
HIV integrase strand transfer inhibitor
Isentress
Raltagrevir
Multi-class Combination Product
Atripla
Efavirenz,emtricitabine and tenofovir

manufacturer
GlaxoSmithKline
Bristol-Meyers Squibb
Roche Pharmaceuticals
Bristol-Meyers Squibb
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Bristol-Meyers Squibb
Gilead Sciences
Gilead Sciences
GlaxoSmithKline
Gilead Sciences
Boehringer Ingelheim
Pfizer
Bristol-Meyers Squibb
Tibotec Therapeutics
Boehringer Ingelheim
Roche Pharmaceuticals
Abbott Laboratories
Merck
Pfizer
Roche Pharmaceuticals
GlaxoSmithKline
Abbott Laboratories
Bristol-Meyers Squibb
GlaxoSmithKline
Hoffman-La Roche
Pfizer
Merck & Co
Brtistol MS and Gilead Sciences

19

01/11/2015

Side Effects
Lipodystrophy
Myopathy
Hepatotoxicity
Immunorestoration
Disease

Rashes

HIV-1 resistance to drugs

20

01/11/2015

Problems with antiretrovirals:

1) Latent reservoirs (memory T-cells, brain microglia).

Thus virus cannot be eradicated by therapy.
2) Emergence and spread of resistant mutants (even to
several drugs).
3) Toxicity and compliance

IV. Viral reservoirs and latency

21

01/11/2015

HIV cellular reservoirs

The major reservoirs of HIV-infected cells includes resting memory
T cells

Is a cure possible?
One case of cure known (Berlin patient)
The cured baby was not cured
Several cases of long term remission known
May depend on size of reservoir (the smaller the better)
and time of therapy. May need novel approaches.

22